CC
BIAF icon

Cypress Capital’s bioAffinity Technologies BIAF Stock Holding History

Cypress Capital’s Portfolio BIAF Stock Details BIAF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7
Closed -$432 – 114
2024
Q2 		$432 Buy
+7
New +$485 ﹤0.01% 357

Other funds holding BIAF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cypress Capital's BIAF Position: Q3 2024 in Review

Cypress Capital sold out of bioAffinity Technologies (BIAF) in Q3 2024, closing a stake of 7 shares — an estimated $432 sold.

Cypress Capital first reported a position in BIAF in Q2 2024 and held it in 1 quarter. The position peaked at $432 in Q2 2024. 14 funds tracked by Wall St. Rank hold BIAF as of Q3 2024.

  • Cypress Capital reported no remaining bioAffinity Technologies position as of Q3 2024 after selling out during the quarter.
  • Cypress Capital sold 7 bioAffinity Technologies shares in Q3 2024, an estimated $432.
  • Cypress Capital first reported a position in bioAffinity Technologies in Q2 2024 and held it in 1 quarter.
  • Cypress Capital's bioAffinity Technologies position peaked at $432 in Q2 2024.
  • 14 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q3 2024.

Based on Cypress Capital's 13F filing for Q3 2024, filed 12 Nov 2024.